Adrian N. Hobden is Pres. Myriad Pharmaceuticals at MYRIAD GENETICS INC (MYGN). They have made 8 open-market trades across 2 companies since 2006, most recently 2010-09-24.
CIK 0001191076
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $88K since 2010, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MYRX | BUY | 2010-03-18 | 2010-03-19 | $4.41 | $88K | N/A | N/A | N/A |
| MYGN | SELL | 2009-05-27 | 2009-05-29 | $34.01 | $1.4M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2009-02-05 | 2009-02-05 | $83.60 | $2.0M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-12-11 | 2008-12-11 | $60.60 | $1.2M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-09-25 | 2008-09-25 | $68.54 | $1.0M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-09-19 | 2008-09-23 | $66.00 | $65K | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-09-17 | 2008-09-19 | $66.49 | $33K | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-08-25 | 2008-08-27 | $65.03 | $1.8M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL · 10b5-1 | 2007-09-25 | 2007-09-27 | $50.00 | $1.0M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL · 10b5-1 | 2007-05-23 | 2007-05-23 | $40.00 | $400K | -0.5% | +0.9% | +0.9% |
| MYGN | SELL · 10b5-1 | 2007-01-03 | 2007-01-03 | $32.00 | $160K | -0.5% | +0.9% | +0.9% |
| MYGN | SELL · 10b5-1 | 2006-04-27 | 2006-04-27 | $26.01 | $130K | -0.5% | +0.9% | +0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.